EP2385145 - Compostions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 16.08.2019 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 07.09.2018 | ||
Former | Grant of patent is intended Status updated on 30.05.2018 | ||
Former | Examination is in progress Status updated on 24.02.2017 | Most recent event Tooltip | 16.07.2021 | Lapse of the patent in a contracting state New state(s): HU | published on 18.08.2021 [2021/33] | Applicant(s) | For all designated states Monogram BioSciences, Inc. 345 Oyster Point Boulevard South San Francisco, CA 94080 / US | [2018/41] |
Former [2011/45] | For all designated states Monogram BioSciences, Inc. 345 Oyster Point Boulevard South San Francisco, CA 94080 / US | Inventor(s) | 01 /
Petropoulos, Christos 415 Garcia Drive Half Moon Bay, CA 94109 / US | [2011/45] | Representative(s) | Donald, Jenny Susan Forresters IP LLP Skygarden Erika-Mann-Strasse 11 80636 München / DE | [2018/41] |
Former [2011/45] | Jones Day Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11 80538 München / DE | Application number, filing date | 11161793.2 | 07.06.2005 | [2011/45] | Priority number, date | US20040577851P | 07.06.2004 Original published format: US 577851 P | [2011/45] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP2385145 | Date: | 09.11.2011 | Language: | EN | [2011/45] | Type: | A3 Search report | No.: | EP2385145 | Date: | 25.11.2015 | Language: | EN | [2015/48] | Type: | B1 Patent specification | No.: | EP2385145 | Date: | 10.10.2018 | Language: | EN | [2018/41] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 23.10.2015 | Classification | IPC: | C12Q1/70, C12N7/00, G01N33/50, C12Q1/66, C07K14/005, C12Q1/04 | [2015/48] | CPC: |
C12Q1/703 (EP,US);
C07K14/005 (EP,US);
C12N7/00 (EP,US);
C12Q1/04 (EP,US);
C12Q1/66 (EP,US);
C12Q1/70 (US);
G01N33/5008 (EP,US);
C12N2740/16021 (US);
C12N2740/16062 (EP,US);
C12N2740/16122 (EP,US);
C12N2770/20021 (US);
C12N2800/107 (EP,US);
|
Former IPC [2015/13] | C12Q1/70, C12N7/00, G01N33/50, C12Q1/66, C07K14/005 | ||
Former IPC [2011/45] | C12Q1/70, C12N7/00 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2016/27] |
Former [2011/45] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | Extension states | AL | 25.05.2016 | BA | 25.05.2016 | HR | 25.05.2016 | LV | 25.05.2016 | MK | 25.05.2016 | YU | 25.05.2016 | Title | German: | Zusammensetzungen und Verfahren zur Bestimmung der Resistenz gegen Vireneintrittshemmer mit rekombinanten Virenassays | [2011/45] | English: | Compostions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays | [2011/45] | French: | Compositions et procédés permettant de déterminer la résistance des inhibiteurs à la saisie de virus à l'aide d'analyses de virus recombinants | [2011/45] | Examination procedure | 25.05.2016 | Examination requested [2016/27] | 01.07.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 12.09.2016 | Amendment by applicant (claims and/or description) | 22.02.2017 | Despatch of a communication from the examining division (Time limit: M06) | 04.09.2017 | Reply to a communication from the examining division | 15.11.2017 | Despatch of a communication from the examining division (Time limit: M04) | 23.03.2018 | Reply to a communication from the examining division | 31.05.2018 | Communication of intention to grant the patent | 31.08.2018 | Fee for grant paid | 31.08.2018 | Fee for publishing/printing paid | 31.08.2018 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP05791148.9 / EP1774049 | Divisional application(s) | EP18199100.1 / EP3483289 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20050791148) is 09.04.2009 | Opposition(s) | 11.07.2019 | No opposition filed within time limit [2019/38] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 12.09.2016 | Request for further processing filed | 12.09.2016 | Full payment received (date of receipt of payment) Request granted | 28.09.2016 | Decision despatched | Fees paid | Renewal fee | 06.06.2011 | Renewal fee patent year 03 | 06.06.2011 | Renewal fee patent year 04 | 06.06.2011 | Renewal fee patent year 05 | 06.06.2011 | Renewal fee patent year 06 | 06.06.2011 | Renewal fee patent year 07 | 14.06.2012 | Renewal fee patent year 08 | 10.06.2013 | Renewal fee patent year 09 | 12.06.2014 | Renewal fee patent year 10 | 10.06.2015 | Renewal fee patent year 11 | 10.06.2016 | Renewal fee patent year 12 | 16.06.2017 | Renewal fee patent year 13 | 10.08.2018 | Renewal fee patent year 14 | Penalty fee | Additional fee for renewal fee | 30.06.2018 | 14   M06   Fee paid on   10.08.2018 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 07.06.2005 | AT | 10.10.2018 | CY | 10.10.2018 | CZ | 10.10.2018 | DK | 10.10.2018 | EE | 10.10.2018 | ES | 10.10.2018 | FI | 10.10.2018 | IT | 10.10.2018 | LT | 10.10.2018 | MC | 10.10.2018 | NL | 10.10.2018 | PL | 10.10.2018 | RO | 10.10.2018 | SE | 10.10.2018 | SI | 10.10.2018 | SK | 10.10.2018 | TR | 10.10.2018 | BG | 10.01.2019 | GR | 11.01.2019 | IS | 10.02.2019 | PT | 10.02.2019 | IE | 07.06.2019 | LU | 07.06.2019 | CH | 30.06.2019 | LI | 30.06.2019 | [2021/33] |
Former [2021/26] | AT | 10.10.2018 | |
CY | 10.10.2018 | ||
CZ | 10.10.2018 | ||
DK | 10.10.2018 | ||
EE | 10.10.2018 | ||
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
IT | 10.10.2018 | ||
LT | 10.10.2018 | ||
MC | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
RO | 10.10.2018 | ||
SE | 10.10.2018 | ||
SI | 10.10.2018 | ||
SK | 10.10.2018 | ||
TR | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
PT | 10.02.2019 | ||
IE | 07.06.2019 | ||
LU | 07.06.2019 | ||
CH | 30.06.2019 | ||
LI | 30.06.2019 | ||
Former [2020/25] | AT | 10.10.2018 | |
CZ | 10.10.2018 | ||
DK | 10.10.2018 | ||
EE | 10.10.2018 | ||
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
IT | 10.10.2018 | ||
LT | 10.10.2018 | ||
MC | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
RO | 10.10.2018 | ||
SE | 10.10.2018 | ||
SI | 10.10.2018 | ||
SK | 10.10.2018 | ||
TR | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
PT | 10.02.2019 | ||
IE | 07.06.2019 | ||
LU | 07.06.2019 | ||
CH | 30.06.2019 | ||
LI | 30.06.2019 | ||
Former [2020/21] | AT | 10.10.2018 | |
CZ | 10.10.2018 | ||
DK | 10.10.2018 | ||
EE | 10.10.2018 | ||
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
IT | 10.10.2018 | ||
LT | 10.10.2018 | ||
MC | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
RO | 10.10.2018 | ||
SE | 10.10.2018 | ||
SI | 10.10.2018 | ||
SK | 10.10.2018 | ||
TR | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
PT | 10.02.2019 | ||
IE | 07.06.2019 | ||
Former [2020/17] | AT | 10.10.2018 | |
CZ | 10.10.2018 | ||
DK | 10.10.2018 | ||
EE | 10.10.2018 | ||
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
IT | 10.10.2018 | ||
LT | 10.10.2018 | ||
MC | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
RO | 10.10.2018 | ||
SE | 10.10.2018 | ||
SI | 10.10.2018 | ||
SK | 10.10.2018 | ||
TR | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
PT | 10.02.2019 | ||
Former [2020/08] | AT | 10.10.2018 | |
CZ | 10.10.2018 | ||
DK | 10.10.2018 | ||
EE | 10.10.2018 | ||
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
IT | 10.10.2018 | ||
LT | 10.10.2018 | ||
MC | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
RO | 10.10.2018 | ||
SE | 10.10.2018 | ||
SI | 10.10.2018 | ||
SK | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
PT | 10.02.2019 | ||
Former [2019/50] | AT | 10.10.2018 | |
CZ | 10.10.2018 | ||
DK | 10.10.2018 | ||
EE | 10.10.2018 | ||
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
IT | 10.10.2018 | ||
LT | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
RO | 10.10.2018 | ||
SE | 10.10.2018 | ||
SI | 10.10.2018 | ||
SK | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
PT | 10.02.2019 | ||
Former [2019/40] | AT | 10.10.2018 | |
CZ | 10.10.2018 | ||
DK | 10.10.2018 | ||
EE | 10.10.2018 | ||
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
IT | 10.10.2018 | ||
LT | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
RO | 10.10.2018 | ||
SE | 10.10.2018 | ||
SK | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
PT | 10.02.2019 | ||
Former [2019/37] | AT | 10.10.2018 | |
CZ | 10.10.2018 | ||
DK | 10.10.2018 | ||
EE | 10.10.2018 | ||
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
IT | 10.10.2018 | ||
LT | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
RO | 10.10.2018 | ||
SE | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
PT | 10.02.2019 | ||
Former [2019/35] | AT | 10.10.2018 | |
CZ | 10.10.2018 | ||
DK | 10.10.2018 | ||
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
IT | 10.10.2018 | ||
LT | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
SE | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
PT | 10.02.2019 | ||
Former [2019/34] | AT | 10.10.2018 | |
DK | 10.10.2018 | ||
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
IT | 10.10.2018 | ||
LT | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
SE | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
PT | 10.02.2019 | ||
Former [2019/26] | AT | 10.10.2018 | |
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
LT | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
SE | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
PT | 10.02.2019 | ||
Former [2019/24] | AT | 10.10.2018 | |
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
LT | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
SE | 10.10.2018 | ||
BG | 10.01.2019 | ||
GR | 11.01.2019 | ||
IS | 10.02.2019 | ||
Former [2019/23] | AT | 10.10.2018 | |
ES | 10.10.2018 | ||
FI | 10.10.2018 | ||
LT | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
BG | 10.01.2019 | ||
IS | 10.02.2019 | ||
Former [2019/22] | FI | 10.10.2018 | |
LT | 10.10.2018 | ||
NL | 10.10.2018 | ||
PL | 10.10.2018 | ||
BG | 10.01.2019 | ||
IS | 10.02.2019 | ||
Former [2019/21] | FI | 10.10.2018 | |
LT | 10.10.2018 | ||
NL | 10.10.2018 | ||
IS | 10.02.2019 | ||
Former [2019/20] | LT | 10.10.2018 | |
NL | 10.10.2018 | ||
Former [2019/17] | NL | 10.10.2018 | Documents cited: | Search | [I]US5837464 (CAPON DANIEL [US], et al) [I] 14-25 * col 1, l 10-16 ; col 10, l 23-54;; figures 2-8 *; | [I]US2002037500 (WHITCOMB JEANNETTE [US]) [I] 14-25 * paragraphs [0064] - [0068] - [0134]; figures 1-4,6-10,12-,15,18-19; example 1; claim 5 *; | [X]US2002182592 (PETROPOULOS CHRISTOS J [US], et al) [X] 1-13 * paragraphs [0074] , [0 82] - [0087] - [ 146] - [0147] - [ 166]; figures 4b, 11-12; examples 1,7; claims 1-13, 21, 34, 37 *; | [X]WO03070985 (VIROLOGIC INC [US], et al) [X] 1-25 * pg 28, l 16 - pg 29, l 1 ; pg 31, l 33ff ; pg 32, l 33 - pg 33, l 13 ; pg 34, l 1-3 ; page 61-62 ; pg 33, l 31-34 ; pg 34, l 12-15 ; pg 55, l 19-29 ; figs 4-5,7-8 ; example 8-9;; figures 1a,1b1 4a; table 4 *; | [A] - Q.-X. HU ET AL, "Evolution of the Human Immunodeficiency Virus Type 1 Envelope during Infection Reveals Molecular Corollaries of Specificity for Coreceptor Utilization and AIDS Pathogenesis", JOURNAL OF VIROLOGY, (20001215), vol. 74, no. 24, doi:10.1128/JVI.74.24.11858-11872.2000, ISSN 0022-538X, pages 11858 - 11872, XP055168702 [A] 1-13 * pg 11860, col 2, para "production of pseudotyped reporter viruses.." ; pg 11859, col 2, para bridging pg 11860 ;;; figures 2-4; table 2 * DOI: http://dx.doi.org/10.1128/JVI.74.24.11858-11872.2000 | [XI] - SI Z ET AL, "Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 101, no. 14, doi:10.1073 PNAS.0307953101, ISSN 0027-8424, (20040406), pages 5036 - 5041, (20040329), XP009166820 [X] 1,3,4,7-11,13 * pg 5036, col 2, para bridging pg 5037 ;;; figures 1-2 * [I] 2,5,6,12 DOI: http://dx.doi.org/10.1073 pnas.0307953101 | [ ] - Z Si ET AL, "SuppText: Small-molecule inhibitors of HIV-1 entry block receptor- induced conformational changes in the viral envelope glycoprotein", PNAS, (20040406), pages 1 - 2, URL: http://www.pnas.org/content/suppl/2004/03/17/0307953101.DC1/07953SuppText.html, (20150211), XP055169026 [ ] * para "plasmids" ; para "HIV-1 infectivity assay" ; * | [XI] - WEI XIPING ET AL, "Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (200206), vol. 46, no. 6, ISSN 0066-4804, pages 1896 - 1905, XP008055247 [X] 1-11,13 * page 6, l 34 - pg 8, l 31 ;; page 1897, column 2, paragraphs PHENOTYPIC,ANALYSIS,OF,T-20,ENV,SENSITIVITY; figures 4-5, 1a, 1b, 2-3; tables 1, 3 * [I] 12 DOI: http://dx.doi.org/10.1128/AAC.46.6.1896-1905.2002 | [A] - P Sista ET AL, "subgroup analysis of baseline (BL) susce ptibility and early virological response to Enfuvirtide in the combined TORO studies", XII International HIV Drug Resistan ce Workshop, Cabo Del Sol, Los Cabos, Mexico, June 10-14, 200, (20030610), page poster 55, URL: http://medadvocates.org/resources/conferences/intdrugresistworkshop/12intdrugresistanceworkshop/final%20sista%20poster%20subgroup%20analysis.pdf, (20151006), XP055218603 [A] 14-25 * column 2, paragraph 3 * | [A] - ANGARANO G ET AL, "Genotype and phenotype resistance: an overview", JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, WICHTIG EDITORE, MILAN, IT, (20000101), vol. 14, no. 1, ISSN 0393-974X, pages 11 - 14, XP008098835 [A] 14-25 * table 1 * | by applicant | WO9727319 | US5837464 | - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 10 | - ALTSCHUL ET AL., NUCLEIC ACIDS RES., (1997), vol. 25, pages 3389 - 3402 | - EISENBERG ET AL., J MOL. BIOL., (1984), vol. 179, pages 125 - 142 | - EISENBERG ET AL., J. MOL. BIOL., (1984), vol. 179, pages 125 - 142 | - MAXAM ET AL., METHODS IN ENZYMOLOGY, (1980), vol. 65, page 499 | - SANGER ET AL., PROC. NATL. ACAD SCI. USA, (1977), vol. 74, page 5463 | - BARNES, W.M., PROC. NATL. ACAD. SCI, USA, (1994), vol. 91, pages 2216 - 2220 | - ADACHI, A., H. E. GENDELMAN, S. KOENIG, T. FOLKS, R. CANEY, A. RABSON, M. A. MARTIN, "Production of Acquired Immunodeficiency Syndrome-associated Retrovirus in Human and Nonhuman Cells Transfected with an Infectious Molecular Clone", J. VIROL., (1986), vol. 59, pages 284 - 291 | - ALKHATIB, G., C. COMBADIERE, C.C. BRODER, Y. FENG, P.E. KENNEDY, P.M. MURPHY, E.A. BERGER, "CC CKR5: A Rantes, MBP-lalpha, MIP-1 Beta Receptor as a Fusion Cofactor for Macrophage-tropic HIV-1", SCIENCE, (1996), vol. 272, pages 1955 - 8 | - ALLAWAY G.P., RYDER A.M., BEAUDRY G.A., MADDON P.J., "Synergistic Inhibition of HIV-1 Envelope- Mediated Cell Fusion by CD4-based Molecules in Combination with Antibodies to Gp120 or Gp41", AIDS RES. HUM. RETROVIRUSES, (1993), vol. 9, pages 581 - 7, XP002927935 | - BABA, M., O. NISHIMURA, N. KANZAKI, M. OKAMOTO, H. SAWADA, Y. IIZAWA, M. SHIRAISHI, Y. ARAMAKI, K. OKONOGI, Y. OGAWA, "A Small- molecule, Nonpeptide CCR5 Antagonist with Highly Potent and Selective Anti-hiv-1 Activity", PROC. NATL. ACAD. SCI. USA, (1999), vol. 96, doi:doi:10.1073/pnas.96.10.5698, pages 5698 - 703, XP000890061 DOI: http://dx.doi.org/10.1073/pnas.96.10.5698 | - BERNARD P., KEZDY KE., VAN MELDEREN L., STEYAERT J., WYNS L., PATO M.L., HIGGINS P.N., COUTURIER M., "The F Plasmid CcdB protein Induces Efficient ATP- dependent Dna Cleavage by Gyrase", J MOL. BIOL., (1993), vol. 23, doi:doi:10.1006/jmbi.1993.1609, pages 534 - 41, XP024008700 DOI: http://dx.doi.org/10.1006/jmbi.1993.1609 | - BERNARD, P., COUTURIER, M., "Cell Killing by the F Plasmid Ccdb protein Involves Poisoning of DNAtopoisomerase II Complexes", J. MOL. BIO., (1992), vol. 226, doi:doi:10.1016/0022-2836(92)90629-X, pages 735 - 45, XP024015338 DOI: http://dx.doi.org/10.1016/0022-2836(92)90629-X | - BLEUL, C.C., M. FARZAN, H. CHOE, C. PAROLIN, I. CLARK-LEWIS, J. SODROSKI, T.A. SPRINGER, "The Lymphocyte Chemoattractant Sdf-1 Is a Ligand for Lestr/fusin and Blocks Hiv-1 Entry", NATURE, (1996), vol. 382, doi:doi:10.1038/382829a0, pages 829 - 33, XP002915916 DOI: http://dx.doi.org/10.1038/382829a0 | - BRIDGER G.J, SKERLJ R.T., PADMANABHAN S., MARTELLUCCI S.A., HENSON G.W., STRUYF S., WITVROUW M., SCHOLS D., DE CLERCQ E., "Synthesis and Structure-activity Relationships of Phenylenebis(methylene)-linked Bis-azamacrocycles That Inhibit HIV-1 and HIV-2 Replication by Antagonism of the Chemokine Receptor CXCR4", J. MED. CHEM., (1999), vol. 42, doi:doi:10.1021/jm990211i, pages 3971 - 81, XP055113935 DOI: http://dx.doi.org/10.1021/jm990211i | - CARPENTER, C.J., COOPER D.A., FISCHL, M.A., GATELL J.M., GAZZARD B.G., HAMMER S.M., HIRSCH M.S., JACOBSEN D.M., KATZENSTEIN D.A.,, "Antiretroviral Therapy in Adults", JAMA, (2000), vol. 283, pages 381 - 89 | - HIV/AIDS Surveillance Report, CDC, (1999), vol. 11 | - COFFIN, J.M., "HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy", SCIENCE, (1995), vol. 267, pages 483 - 489 | - GERDES, K., L.K. POULSEN, T. THISTED, A.K. NIELSON, J. MARTINUSSEN, P.H. ANDREASEN, "The Hok Killer Gene Family in Gram-negative Bacteria", THE NEW BIOLOGIST, (1990), vol. 2, pages 946 - 956, XP009031568 | - HERTOGS, K., M.P. DE BETHUNE, V. MILLER, T. IVENS, P. SCHEL, A. V. CAUWENBERGE, C. VAN DEN EYNDE, V. VAN GERWEN, H. AZIJN, M. VAN, "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Subjects Treated with Antiretroviral Drugs", ANTIMICROB. AGENTS CHEMOTHER, (1998), vol. 42, pages 269 - 276 | - HWANG, J.-J., L. LI, W.F. ANDERSON, "A Conditional Self-inactivating Retrovirus Vector That Uses a Tetracycline-responsive Expression System", J. VIROL., (1997), vol. 71, pages 7128 - 7131 | - JAPOUR, A. J., D. L. MAYERS, V. A. JOHNSON, D. R. KURITZKES, L. A. BECKETT, J. M. ARDUINO, J. LANE, B. R.J., P.S. REICHELDERFER, R, "Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodefiency Virus Type 1 Isolates", ANTIMICROB. AGENTS CHEMOTHER, (1993), vol. 37, pages 1095 - 1101 | - JUDICE J.K., TOM J.Y., HUANG W., WRIN T., VENNARI J., PETROPOULOS C.J., MCDOWELL R.S., "Inhibition HIV Type 1 Infectivity by Constrained Alphahelical Peptides: Implications for the Viral Fusion Mechanism", PROC. NATL. ACAD. SCI. USA, (1997), vol. 94, doi:doi:10.1073/pnas.94.25.13426, pages 13426 - 30, XP002126803 DOI: http://dx.doi.org/10.1073/pnas.94.25.13426 | - KILBY JM, HOPKINS S, VENETTA TM, DIMASSIMO B, CLOUD GA, LEE JY, ALLDRDGE L, HUNTER E, LAMBERT D, BOLOGNESI D, "Potent Suppression ofHIV-1 I Replication in Humans by T-20, a Peptide Inhibitor of Gp41-mediated Virus Entry", NAT MED., (1998), vol. 4, doi:doi:10.1038/3293, pages 1302 - 7, XP000909990 DOI: http://dx.doi.org/10.1038/3293 | - MASCOLA, J.R., G. STIEGLER, T.C. VANCOTT, H. KATINGER, C.B. CARPENTER, C.E. HANSON, H. BEARY, D. HAYES, S.S. FRANKEL, D.L. BIRX, "Protection of Macaques Against Vaginal Transmission of a Pathogenic HIV-1/siv Chimeric Virus by Passive Infusion of Neutralizing Antibodies", NATURE MED., (2000), vol. 6, doi:doi:10.1038/72318, pages 207 - 210, XP002615883 DOI: http://dx.doi.org/10.1038/72318 | - MIYOSHI, H., B. ULRIKE, M. TAKAHASHI, F.H. GAGE, LM. VERMA, "Development of a Self-inactivating Lentivirus Vector", J. VIROL., (1998), vol. 72, pages 8150 - 5157 | - NAVIAUX, R.K., E. COSTANZI, M. HAAS, LM. VERMA, "The Pcl Vector System: Rapid production of Helper-free, High-titer, Recombinant Retroviruses", J. VIROL., (1996), vol. 70, pages 5701 - 5705 | - PETROPOULOS, C.J., N.T. PARKIN, K.L. LIMOLI, Y.S. LIE, T. WRIN, W. HUANG, H. TIAN, D. SMITH, G.A. WINSLOW, D. CAPON, "A Novel Phenotypic Drug Susceptibility Assay for HIV-1", ANTIMICROB. AGENTS & CHEM., (2000), vol. 44, doi:doi:10.1128/AAC.44.4.920-928.2000, pages 920 - 928, XP002962272 DOI: http://dx.doi.org/10.1128/AAC.44.4.920-928.2000 | - PIKETTY, C., E. RACE, P. CASTIEL, L. BELEC, G. PEYTAVIN, A. SI-MOHAMED, G. GONZALEZ-CANALI, L. WEISS, F. CLAVEL, M. KAZATCHKINE, "Efficacy of a Five-drug Combination Including Ritonavir, Saquinavir and Efavirenz in Subjects Who Failed on a Conventional Triple-drug Regimen: Phenotypic Resistance to protease Inhibitors predicts Outcome of Therapy", AIDS, (1999), vol. 13, pages F71 - F77 | - PORTER, C.C., K.V. LUKACS, G. BOX, Y. TAKEUCHI, M.K.L. COLLINS, "Cationic Liposomes Enhance the Rate of Transduction by a Recombinant Retroviral Vector in Vitro and in Vivo", J. VIROL., (1998), vol. 72, pages 4832 - 4840 | - REIMANN K.A., CATE R.L., WU Y., PALMER L., OLSON D., WAITE B.C., LETVIN N.L., BURKLY L.C., "In Vivo Administration of CD4-specific Monoclonal Antibody: Effect on provirus Load in Rhesus Monkeys Chronically Infected with the Simian Immunodeficiency Virus of Macaques", AIDS RES. HUM. RETROVIRUSES, (1995), vol. 11, pages 517 - 25 | - RICHMAN, D., "Nailing down Another HIV Target", NATURE MED., (1998), vol. 4, pages 1232 - 1233 | - RIMSKY, L.T., D.C. SHUGARS, T.J. MATTHEWS, "Determinants of Human Immunodeficiency Virus Type 1 Resistance to Gp41-derived Inhibitory Peptides", J. VIROL., (1998), vol. 72, pages 986 - 993, XP000909961 | - RODRIGUEZ-ROSADO, R., BRIONES, C., SORIANO, V., "Introduction of HIV Drug-resistance Testing in Clinical Practice", AIDS, (1999), vol. 13, pages 1007 - 1014 | - SCHINAZI, R.F., LARDER, B.A., MELLORS, J.W., "Mutations in Retroviral Genes Associated with Drug Resistance", INTL. ANTIVIRAL NEWS, (1999), vol. 7, pages 46 - 49 | - SHI C., J.W. MELLORS, "A Recombinant Retroviral System for Rapid in Vivo Analysis of Human Immunodefiency Virus Type 1 Susceptibility to Reverse Transcriptase Inhibitors", ANTIMICROB. AGENTS CHEMOTHER, (1997), vol. 41, pages 2781 - 2785, XP002924447 | - STEPHENSON, J., "New Class of Anti-HIV Drugs", JAMA, (1994), vol. 282 | - WILD, C., T. OAK, C. MCDANAL, D. BOLOGNESI, T. MATTHEWS, "A Synthetic Peptide Inhibitor ofHIV Replication: Correlation Between Solution Structure and Viral Inhibition", PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, doi:doi:10.1073/pnas.89.21.10537, pages 10537 - 10541, XP000608915 DOI: http://dx.doi.org/10.1073/pnas.89.21.10537 | - ZENNOU, V., F. MAMMAMO, S. PAULOUS, D. MATHEZ, F. CALVEL, "Loss of Viral Fitness Associated with Multiple Gag and Gag-pol processing Defects in Human Immunodefiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors in vivo", J. VIROL, (1998), vol. 72, pages 3300 - 06, XP002232098 | - ZIERMANN, R., K. LIMOLI, K. DAS, E. ARNOLD, C.J. PETROPOULOS, N.T. PARKIN, "A Mutation in HIV-1 Protease, N88s, That Causes in Vitro Hypersensitivity to Amprenavir", J. VIROL., (2000), vol. 74, doi:doi:10.1128/JVI.74.9.4414-4419.2000, pages 4414 - 4419, XP002908352 DOI: http://dx.doi.org/10.1128/JVI.74.9.4414-4419.2000 | US20010874475 | US20020077027 |